Eplerenon zamiast spironolaktonu w leczeniu niewydolności serca – opis przypadku Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2017
Słowa kluczowe:
eplerenon, spironolakton, antagoniści aldosteronu, niewydolność serca
##plugins.themes.bootstrap3.article.main##
Abstrakt
Przedstawiono przypadek pacjenta, u którego zastosowanie spironolaktonu w leczeniu niewydolności serca spowodowało wystąpienie działań niepożądanych, co wymagało zastąpienia tego leku eplerenonem. Omówiono zalety eplerenonu jako antagonisty aldosteronu lepiej tolerowanego niż spironolakton.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Jędrusik , P. (2017). Eplerenon zamiast spironolaktonu w leczeniu niewydolności serca – opis przypadku . Medycyna Faktów , 10(2(35), 142-145. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2155
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
2. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
3. Zannad F., McMurray J.J.V., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
4. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.
5. Yancy C.W., Jessup M., Bozkurt B. et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 62: e147-e239.
6. Yancy C.W., Jessup M., Bozkurt B. et al.: 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J. Am. Coll. Cardiol. 2017. DOI: 10.1016/j.jacc.2017.04.025.
7. Pitt B., Pfeffer M.A., Assmann S.F. et al.: Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014; 370: 1383-1392.
8. Pfeffer M.A., Claggett B., Assmann S.F. et al.: Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
9. Chatterjee S., Moeller C., Shah N. et al.: Eplerenone is not superior to older and less expensive aldosterone antagonists. Am. J. Med. 2012; 125: 817-825.
10. Danjuma M.I., Mukherjee I., Makaronidis J., Osula S.: Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr. Hypertens. Rep. 2014; 16: 414-423.
2. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
3. Zannad F., McMurray J.J.V., Krum H. et al.: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
4. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016; 37: 2129-2200.
5. Yancy C.W., Jessup M., Bozkurt B. et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 62: e147-e239.
6. Yancy C.W., Jessup M., Bozkurt B. et al.: 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J. Am. Coll. Cardiol. 2017. DOI: 10.1016/j.jacc.2017.04.025.
7. Pitt B., Pfeffer M.A., Assmann S.F. et al.: Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014; 370: 1383-1392.
8. Pfeffer M.A., Claggett B., Assmann S.F. et al.: Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
9. Chatterjee S., Moeller C., Shah N. et al.: Eplerenone is not superior to older and less expensive aldosterone antagonists. Am. J. Med. 2012; 125: 817-825.
10. Danjuma M.I., Mukherjee I., Makaronidis J., Osula S.: Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr. Hypertens. Rep. 2014; 16: 414-423.